CA9 and acute myeloid leukemia: As shown in Figure 6A–O, four out of five patients showed significantly increased CA IX and/or CA XII staining in leukaemic blasts that escaped chemotherapeutic elimination strongly suggesting that dual CA IX/XII inhibition may be of value as an adjunct to chemotherapy in the management of AML.